Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | HPGD | P15428 | 4/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18733286 | 0.91 | KDM4E (0.79) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL3057182 | 0.91 | FLT3 (0.64) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL2924029 | 0.88 | KDM4E (0.65) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL6599162 | 0.88 | KDM4E (0.77) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL9263164 | 0.86 | KDM4E (0.80) | KDM4EALDH1A1HPGDHSD17B10PDGFRB | |
| SCHEMBL18733290 | 0.86 | ALDH1A1 (0.63) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL20944325 | 0.85 | GABRA1 (0.64) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL7431714 | 0.85 | MEN1 (0.63) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL13133298 | 0.85 | KDM4E (0.81) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL630515 | 0.85 | SRD5A2 (1.00) | KDM4EALDH1A1HPGDHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948454-B1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENT & IND RES AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETI (IN) | 2017-05-31 | — | — | EP | claimed |
| US-9447105-B2 | Triazine compounds and a process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-09-20 | — | — | US | claimed |
| US-20150353566-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-12-10 | — | — | US | claimed |
| EP-2948454-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) (IN) | 2015-12-02 | — | — | EP | claimed |
| WO-2014115171-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-07-31 | — | — | WO | claimed |
| CN-122071464-A | Heterocyclic compound, pharmaceutical composition thereof and application thereof | 上海璎黎药业有限公司 | 2026-05-22 | — | — | CN | disclosed |
| WO-2024218227-A1 | INDOLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | UNIVERSIDAD DE ALCALÁ (ES) | 2024-10-24 | — | — | WO | disclosed |
| EP-4450494-A1 | INDOLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | Consejo Superior De Investigaciones Científicas (ES) | 2024-10-23 | — | — | EP | disclosed |
| US-20220017513-A1 | AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-3892616-A1 | AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| CN-105816453-B | Substituted tricyclic acid derivatives as S1P1 receptor agonists for the treatment of autoimmune and inflammatory disorders | 艾尼纳制药公司 | 2021-03-05 | — | — | CN | disclosed |
| WO-2020114475-A1 | AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE | 上海济煜医药科技有限公司 | 2020-06-11 | — | — | WO | disclosed |
| US-5428043-A | Tricyclic-cyclic amines as novel cholinesterase inhibitors | PFIZER INC. (US) | 1995-06-27 | — | — | US | disclosed |
| WO-1994014434-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
| EP-0544821-A1 | INDOLE DERIVATIVES AS ANTIALLERGY AND ANTIINFLAMMATORY AGENTS. | PFIZER (US) | 1993-06-09 | — | — | EP | disclosed |
| WO-1992021678-A1 | LIPOXYGENASE INHIBITING PYRROLO [1,2a]INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-12-10 | — | — | WO | disclosed |
| WO-1992006088-A1 | INDOLE DERIVATIVES AS ANTIALLERGY AND ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1992-04-16 | — | — | WO | disclosed |
| EP-0441517-A2 | Tricyclic amines as novel cholinesterase inhibitors | PFIZER INC. (US) | 1991-08-14 | — | — | EP | disclosed |
| EP-0105763-B1 | INDOLE COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | KOWA COMPANY, LTD. (JP) | 1988-01-20 | — | — | EP | disclosed |
| EP-0105763-A1 | Indole compounds, their preparation and pharmaceutical compositions comprising them | KOWA COMPANY, LTD. (JP) | 1984-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353566-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | TPH2, IDO2, INMT | KDM4E 862/4885ALDH1A1 2885/4885HPGD 2149/4885 |
| US-20220017513-A1 | AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE | S1PR1, S1PR2, S1PR3 | KDM4E 2176/4885ALDH1A1 1752/4885HPGD 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.